bluebird bio (NASDAQ:BLUE) had its price objective raised by BTIG Research to $250.00 in a research note issued to investors on Thursday morning, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.
BLUE has been the topic of a number of other reports. Maxim Group reaffirmed a hold rating and issued a $200.00 target price on shares of bluebird bio in a report on Thursday, February 22nd. Leerink Swann cut shares of bluebird bio from an outperform rating to a market perform rating and lifted their target price for the company from $162.00 to $194.00 in a report on Thursday, January 25th. CIBC began coverage on shares of bluebird bio in a report on Thursday, December 21st. They issued a market perform rating on the stock. BidaskClub raised shares of bluebird bio from a buy rating to a strong-buy rating in a report on Friday, January 26th. Finally, Oppenheimer started coverage on shares of bluebird bio in a research report on Wednesday, December 20th. They issued a market perform rating on the stock. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Hold and an average price target of $187.60.
bluebird bio (NASDAQ BLUE) opened at $231.95 on Thursday. The company has a market cap of $11,590.00, a price-to-earnings ratio of -43.11 and a beta of 2.05. bluebird bio has a 1-year low of $74.45 and a 1-year high of $234.25.
In other bluebird bio news, insider David Davidson sold 6,000 shares of the business’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $180.30, for a total transaction of $1,081,800.00. Following the sale, the insider now directly owns 21,977 shares in the company, valued at approximately $3,962,453.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nick Leschly sold 117,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the sale, the insider now owns 293,232 shares in the company, valued at $53,978,146.56. The disclosure for this sale can be found here. Insiders have sold a total of 182,098 shares of company stock worth $33,999,709 over the last 90 days. Insiders own 3.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of BLUE. Hanseatic Management Services Inc. boosted its position in shares of bluebird bio by 14.6% in the 4th quarter. Hanseatic Management Services Inc. now owns 2,334 shares of the biotechnology company’s stock worth $416,000 after buying an additional 298 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in bluebird bio by 6.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,444 shares of the biotechnology company’s stock valued at $748,000 after purchasing an additional 330 shares during the last quarter. C WorldWide Group Holding A S raised its stake in bluebird bio by 17.8% in the 3rd quarter. C WorldWide Group Holding A S now owns 2,474 shares of the biotechnology company’s stock valued at $340,000 after purchasing an additional 374 shares during the last quarter. Teacher Retirement System of Texas raised its stake in bluebird bio by 13.4% in the 3rd quarter. Teacher Retirement System of Texas now owns 3,687 shares of the biotechnology company’s stock valued at $506,000 after purchasing an additional 437 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in bluebird bio by 2.3% in the 4th quarter. Macquarie Group Ltd. now owns 19,102 shares of the biotechnology company’s stock valued at $3,402,000 after purchasing an additional 438 shares during the last quarter.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.themarketsdaily.com/2018/03/12/btig-research-boosts-bluebird-bio-blue-price-target-to-250-00.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.